Mumbai, (Udaipur Kiran). Shares of Alembic Pharmaceuticals traded higher after the company received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydrochloride Tablets USP in 30 mg, 60 mg, 90 mg and 120 mg strengths.
The stock was trading at Rs 928.00, up 25.20 points or 2.79% from its previous close of Rs 902.80. It opened at Rs 919.00 and touched a high of Rs 928.95 and a low of Rs 911.50. A total of 3,191 shares were traded so far.
The BSE Group ‘A’ stock, with a face value of Rs 2, recorded a 52-week high of Rs 1,122.40 on 6 January 2025 and a 52-week low of Rs 725.60 on 3 March 2025. Over the last week, the scrip traded between Rs 930.70 and Rs 900.00. The company’s current market capitalisation stands at Rs 18,114.27 crore.
Promoters hold 69.74% of the company’s equity, while institutions hold 20.35% and non-institutional investors hold 9.92%.
USFDA Approval Details
The approved ANDA is therapeutically equivalent to the reference listed drug Cardizem Tablets (30 mg, 60 mg, 90 mg, 120 mg) of Bausch Health US, LLC. Diltiazem Hydrochloride Tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
Alembic Pharmaceuticals now has a cumulative total of 230 ANDA approvals from the USFDA, including 210 final approvals and 20 tentative approvals.
Alembic Pharma is engaged in the manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients, supported by vertical integration capabilities.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
